Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPERBOLIC study
2025-521583-35-00Phase 2Authorised
- Sponsor
- Vita-Salute San Raffaele University
- Start
- Feb 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cemiplimab, pemetrexed, carboplatin, paclitaxel and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Vita-Salute San Raffaele University. Primary endpoint: HPD and ED rate. Planned start Feb 2026; status: authorised.
02
Drugs
cemiplimabpemetrexedcarboplatinpaclitaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521583-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521583-35-00.